Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma.pdf (3.09 MB)
0/0

Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells.

Download (3.09 MB)
journal contribution
posted on 22.11.2019 by Cormac J. Jennings, Najihah Zainal, Izyan MM Dahlan, Elaine W. Kay, Brian J. Harvey, Warren Thomas

INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare but highly aggressive malignancy most often associated with exposure to asbestos. Recent evidence points to oestrogen receptor (ER)-β having a tumour-suppressor role in MPM progression, and this raises the question of whether selective modulators of ERs could play a role in augmenting MPM therapy.

MATERIALS AND METHODS: We investigated the action of tamoxifen in inhibiting the growth and modulating the cisplatin sensitivity of four MPM cell lines.

RESULTS: Tamoxifen inhibited the growth of MPM cells and also modulated their sensitivity to cisplatin. The MPM cell lines expressed ERβ, but the actions of tamoxifen were not blocked by antagonism of nuclear ERs. Tamoxifen treatment repressed the expression of cyclins by MPM cells, resulting in cell-cycle arrest and caspase-3-coupled apoptosis signaling.

CONCLUSION: The ER-independent actions of tamoxifen on MPM cell proliferation and cell-cycle progression may have clinical benefits for a subset of patients with MPM.

Funding

This work was supported by the Health Research Board, Ireland (Ph.D. Scholarship to CJ); and the Royal College of Surgeons in Ireland Alumni Student Research Programme (Summer Research Scholarship to NZ). MPM tumour biopsy specimens were provided by Professor Bruno Murer, Dell’Angelo Hospital Mestre-Venice, Italy.

History

Comments

This article is also available at http://ar.iiarjournals.org/content/36/11/5905.long

Published Citation

Jennings CJ, Zainal N, Dahlan IMM, Kay EW, Harvey BJ, Thomas W. Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells. Anticancer Research. 2016;36(11):5905-5913.

Publication Date

01/11/2016

Publisher

J.G. Delinassios, Anticancer Research

PubMed ID

27793915

Exports

Logo branding

Exports